Spyre Therapeutics

(NASDAQ) SYRE

Current Price$74.53

Market Cap$6.18B

Since IPO (2016)-76%

5 Year-63%

1 Year+379%

1 Month+58%

Spyre Therapeutics Financials at a Glance

Market Cap

$6.18B

Revenue (TTM)

$90.49M

Net Income (TTM)

$155.20M

EPS (TTM)

$-2.08

P/E Ratio

-34.60

Dividend

$0.00

Beta (Volatility)

0.70 (Low)

Dividend

$0.00

Beta (Volatility)

0.70 (Low)

Price

$74.53

Volume

35,009

Open

$72.32

Price

$74.53

Volume

35,009

Open

$72.32

Previous Close

$74.53

Daily Range

$72.11 - $74.84

52-Week Range

$12.29 - $75.00

Dividend

$0.00

Beta (Volatility)

0.70 (Low)

Price

$74.53

Volume

35,009

Open

$72.32

Previous Close

$74.53

Daily Range

$72.11 - $74.84

52-Week Range

$12.29 - $75.00

SYRE News

Spyre CEO Sells $740K in Stock After 300% Surge as Key Q3 Data Nears

Jonathan PoncianoApr 8, 2026

Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means

Seena HassounaMar 18, 2026

Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million

Jonathan PoncianoFeb 23, 2026

SYRE: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Spyre Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

102

CEO

Cameron Turtle, PhD

Website

www.spyre.com

Headquarters

Waltham, MA 02453, US

SYRE Financials

Key Financial Metrics (TTM)

Gross Margin

Operating Margin

-2%

Net Income Margin

-2%

Return on Equity

-22%

Return on Capital

-29%

Return on Assets

-20%

Earnings Yield

-2.89%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$6.18B

Shares Outstanding

86.02M

Volume

35.01K

Avg. Volume

1.00M

Financials (TTM)

Gross Profit

$171.65M

Operating Income

$209.56M

EBITDA

$209.56M

Operating Cash Flow

$169.25M

Capital Expenditure

$0.00

Free Cash Flow

$169.25M

Cash & ST Invst.

$756.53M

Total Debt

$0.00

Spyre Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

$90.49M

N/A

Gross Profit

$45.25M

N/A

Gross Margin

50.00%

N/A

Market Cap

$6.18B

N/A

Market Cap/Employee

$84.71M

N/A

Employees

N/A

Net Income

$62.53M

-11.1%

EBITDA

$62.53M

-2.1%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Net Cash

$756.53M

+25.4%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-19.95%

N/A

Return on Invested Capital

-29.14%

N/A

Free Cash Flow

$44.58M

-19.8%

Operating Cash Flow

$44.58M

-19.8%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

CLDXCelldex Therapeutics, Inc.

CLDXCelldex Therapeutics, Inc.$32.88+2.30%

ZYMEZymeworks Inc.

ZYMEZymeworks Inc.$27.54-1.04%

PHVSPharvaris N.V.

PHVSPharvaris N.V.$31.01+3.96%

IMNMImmunome, Inc.

IMNMImmunome, Inc.$22.94-0.04%

NTLAIntellia Therapeutics, Inc.

NTLAIntellia Therapeutics, Inc.$13.48+8.32%

ARDXArdelyx, Inc.

ARDXArdelyx, Inc.$6.33+5.32%

MAZEMaze Therapeutics, Inc.

MAZEMaze Therapeutics, Inc.$26.58+3.50%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

INTCIntel

INTCIntel$94.48-0.00%

NOKNokia

NOKNokia$12.91+0.04%

SOFISoFi Technologies

SOFISoFi Technologies$16.10+0.04%

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.63+0.10%

MARAMara Holdings

MARAMara Holdings$11.99+0.12%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$63.54+0.03%

FFord Motor Company

FFord Motor Company$12.08-0.01%

Questions About SYRE

What is the current price of Spyre Therapeutics?

Spyre Therapeutics is trading at $74.53 per share.

What is the 52-week range for Spyre Therapeutics?

Over the past 52 weeks, Spyre Therapeutics has traded between $12.29 and $75.00.

How much debt does Spyre Therapeutics have?

As of the most recent reporting period, Spyre Therapeutics reported total debt of N/A.

How much cash does Spyre Therapeutics have on hand?

Spyre Therapeutics reported $85.72M in cash and cash equivalents in its most recent financial results.

What is Spyre Therapeutics’s dividend yield?

Spyre Therapeutics does not currently have a dividend yield.

Spyre Therapeutics

Spyre Therapeutics Financials at a Glance

SYRE News

Spyre CEO Sells $740K in Stock After 300% Surge as Key Q3 Data Nears

Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means

Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million

Spyre Therapeutics' CEO Sells 15,000 Shares

Spyre (SYRE) Q2 R&D Up 23% Loss Narrows

Why Aeglea BioTherapeutics Stock Is Way Down Today

George Soros Bought This Under-the-Radar Biotech Stock: Should You?

SYRE: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Spyre Therapeutics

SYRE Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Spyre Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About SYRE

What is the current price of Spyre Therapeutics?

What is the 52-week range for Spyre Therapeutics?

How much debt does Spyre Therapeutics have?

How much cash does Spyre Therapeutics have on hand?

What is Spyre Therapeutics’s dividend yield?

Premium Investing Services